Cloning of a novel T-cell protein FYB that binds FYN and SH2-domain-containing leukocyte protein 76 and modulates interleukin 2 production - PubMed (original) (raw)

Cloning of a novel T-cell protein FYB that binds FYN and SH2-domain-containing leukocyte protein 76 and modulates interleukin 2 production

A J da Silva et al. Proc Natl Acad Sci U S A. 1997.

Abstract

T cell receptor zeta (TcRzeta)/CD3 ligation initiates a signaling cascade that involves src kinases p56(lck) and zeta-associated protein 70, leading to the phosphorylation of substrates such as TcRzeta, Vav, SH2-domain-containing leukocyte protein 76 (SLP-76), cbl, and p120/130. FYN binding protein (FYB or p120/130) associates with p59(fyn), the TcRzeta/CD3 complex, and becomes tyrosine-phosphorylated in response to receptor ligation. In this study, we report the cDNA cloning of human and murine FYB and show that it is restricted in expression to T cells and myeloid cells and possesses an overall unique hydrophilic sequence with several tyrosine-based motifs, proline-based type I and type II SH3 domain binding motifs, several putative lysine/glutamic acid-rich nuclear localization motifs, and a SH3-like domain. In addition to binding the src kinase p59(fyn), FYB binds specifically to the hematopoietic signaling protein SLP-76, an interaction mediated by the SLP-76 SH2 domain. In keeping with this, expression of FYB augmented interleukin 2 secretion from a T cell hybridoma, DC27.10, in response to TcRzeta/CD3 ligation. FYB is therefore a novel hematopoietic protein that acts as a component of the FYN and SLP-76 signaling cascades in T cells.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Sequence and structural motifs of FYB. (A) Overall amino acid sequence of human (upper sequence) and murine (lower sequence) FYB cDNAs. Representation depicts overall structure and the location of potential motifs that include a proline-rich region followed by a YEDI motif, two putative lysine/glutamic acid/arginine-rich nuclear localization motifs, and a SH3-like domain. Amino acid sequences of human and murine FYB (783 and 774 residues, respectively) show the position of the type I and type II proline-rich SH3 domain recognition motifs (underlined with bold line), the YEDI motif (indicated within shaded box), putative nuclear localization motifs (underlined with double line), and the C-terminal SH3-like domain (indicated within open box). (B) Schematic comparison of the FYB SH3-like domain with other SH3 domains. SH3-like domain shows particular homology to the SH3 domains of the protein-tyrosine kinases such as B lymphocyte kinase, p60yes, Bruton’s/agammaglobulinemia tyrosine kinase, and CRK-like protein (CRKL). Similarity is also seen with SH3 domain of a C. elegans SH3-carrying-protein and a Drosophila SH2/SH3 adaptor protein. Conserved SH3 domain residues include the βa region valine (residue 707), a RT loop tyrosine (residue 709), aspartic acid (residue 726), and a glycine (residue 732), a βd region glycine-tyrosine (residues 756–757), and a tyrosine (residue 762) proximal to βe region. (C) FYB cDNA clone generates polypeptide recognized by anti-FYB antiserum. HA-tagged FYB cDNA was expressed in COS (lane 2) and DC27.10 (lane 6) cells by using electroporation. Cell lysates were subjected to immunoprecipitation using anti-HA (lanes 1, 2, 5, and 6) or anti-FYB (lane 4) and precipitates were immunoblotted with anti-FYB serum.

Figure 2

Figure 2

Expression of FYB is restricted to T and myeloid cells. (Top) Northern blot hybridization with the human FYB cDNA clone against CLONTECH poly(A)+ RNA purified from spleen (lane 1), thymus (lane 2), prostate (lane 3), testis (lane 4), ovary (lane 5), small intestine (lane 6), colon (lane 7), peripheral blood lymphocytes (lane 8), heart (lane 9), brain (lane 10), placenta (lane 11), lung (lane 12), liver (lane 13), and skeletal muscle (lane 14). (Middle) Hybridization of FYB cDNA against total RNA purified from human peripheral blood lymphocyte-purified T cells (lane 1), Jurkat cells (lane 2), HPB-ALL cells (lane 3), tonsil-purified B-cells (lane 4), Ramos cells (lane 5), Daudi cells (lane 6), lung cell line Cala (lane 7), uterine cell line Hela (lane 8), breast cell line HLB-100 (lane 9), and myeloid cell line HL-60 (lane 10). (Lower) Parallel immunoblot analysis of cells from Middle with anti-FYB antiserum.

Figure 3

Figure 3

FYB and p59fyn(T) associate in COS cells. COS cells were transfected with pSRα vector control (lanes 1, 5, 9, and 13), pSRα-FYB(Ha) (lanes 2, 6, 10, and 14), pSRαFyn (lanes 3, 7, 11, and 15), or pSRα-FYB(Ha) and pSRαFyn (lanes 4, 8, 12, and 16). Cell lysates were incubated with anti-Ha mAb to precipitate FYB or with anti-fyn as indicated, precipitates were separated by SDS/PAGE, and samples were analyzed with anti-phosphotyrosine (lanes 1–8), anti-FYB (lanes 9–12), or anti-Fyn (lanes 13–16).

Figure 4

Figure 4

FYB associates with SLP-76 SH2 in T cells. (A) FYB associates with SLP-76. Lysates from DC27.10 cells were subjected to precipitation with preimmune (lanes 1 and 3), anti-SLP-76 (lanes 2 and 4), anti-FYB (lane 5), or GST (lanes 6 and 8) and GST–FYB (lanes 7 and 9) fusion proteins. Precipitates were then analyzed by immunoblotting with anti-phosphotyrosine mAb 4G10 (lanes 1, 2, 6, and 7), anti-FYB (lanes 3–5), or anti-SLP-76 (lanes 8 and 9). (B) SLP-76 SH2 domain specifically recognizes FYB from T cells. DC27.10-derived lysates were incubated with GST fusion proteins as indicated: GST alone (lane 1), GRB-2 (lane 2), SH2-p85 (lane 3), SH2-HCP (lane 4), SH2-SYP (lane 5), SH2-SLP-76 (lane 6), and SH2-FYN (lane 7). Precipitates were separated by SDS/PAGE and analyzed by immunoblotting with anti-FYB. (C) SLP-76 SH2 domain preferentially binds to FYB from T cells. Cell lysates from DC27.10 cells (lanes 1–4) and Jurkat (lanes 5–8) were incubated with GST (lanes 1, 3, 5, and 7) or GST–SH2-SLP-76 fusion protein (lanes 2, 4, 6, and 8) and subjected to immunoblotting analysis with anti-phosphotyrosine (lanes 1, 2, 5, and 6) or anti-FYB (lanes 3, 4, 7, and 8) serum.

Figure 5

Figure 5

FYB up-regulates TcRζ/CD3-induced IL-2 production. FYB transfected DC27.10 cells showed a 3- to 5-fold augmentation of IL-2 production in response to anti-CD3 alone or anti-CD3 plus phorbol ester. FYB cDNA (at 0.1, 0.25, 1.0, or 4.0 μg per 106 cells) or mock-transfected DC27.10 cells (32) were incubated overnight with medium alone, anti-CD3, or anti-CD3 mAb plus phorbol 12-myristate 13-acetate, as indicated. Cell culture supernatants were assayed for IL-2 by a bioassay using CTLL-2 cells.

Similar articles

Cited by

References

    1. Rudd C E, Janssen O, Cai Y C, da Silva A J, Raab M, Prasad K V. Immunol Today. 1994;15:225–234. - PubMed
    1. Mustelin T. Immunity. 1994;1:351–356. - PubMed
    1. Wange R L, Samelson L E. Immunity. 1996;5:197–205. - PubMed
    1. Chan A C, Iwashima M, Turck C W, Weiss A. Cell. 1992;71:649–662. - PubMed
    1. Iwashima M, Irving B A, van Oers N S C, Chan A C, Weiss A. Science. 1994;263:1136–1139. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources